Tag:Food and Drug Administration (FDA)

Professor Lietzan Cowrites Chapter in FDA in the 21st Century

September 10th, 2015

Professor Erika Lietzan recently cowrote an essay in a book published by Columbia University Press, FDA in the 21st Century, with Professor Henry Grabowski of Duke University. The book chapter, “FDA Regulation of Biosimilars,” discusses the Biologics

Read More

Professor Lietzan Publishes on Regulation of Biosimilars and Biotechnology Drugs, Devices

May 27th, 2015

Professor Erika Lietzan is the editor of a recently-published book on premarket and postmarket regulation of biotechnology drugs and devices. The book, Medical Biotechnology: Premarket and Postmarket Regulation, contains a chapter co-authored by Professor Lietzan that focuses

Read More

Professor Lietzan’s Presentation on Biosimilar Biological Products Featured by The Pink Sheet

October 15th, 2014

Professor Erika Lietzan’s presentation at an annual meeting of the Drug Information Association was covered by The Pink Sheet, a publication that reports on “regulatory, legislative, legal and business developments” in the biopharmaceutical industry. Professor Lietzan was the only law

Read More

Professor Lietzan Presents at Drug Information Association Meeting

September 29th, 2014

Professor Erika Lietzan presented at an annual meeting of the Drug Information Association that focused on biosimilar biological products, or products that are “highly similar” to a “reference product, notwithstanding minor differences in clinically inactive components,” according

Read More

Colleagues Select Prof. Lietzan for Best Lawyers in America

August 22nd, 2014

Prof. Erika Lietzan was recently selected by her peers for inclusion in The Best Lawyers in America© 2015, in the fields of Food and Drug Administration (FDA) Law and Biotechnology Law.  More than 52,000 attorneys across the

Read More